Zytronic (ZYT:AIM) provided a detailed investor update outlining progress on its agreed strategy to wind down operations, liquidate assets, and return all cash to shareholders. The Board confirmed that the process is well advanced, with plant and equipment sold, a property disposal agreed, and liquidation expected to commence in October 2025. Shareholders are forecast to receive between 48p and 58p per share, with confidence expressed toward achieving the upper end of that range.

The update also addressed a shareholder requisition led by Tom Spain and Glenn Arnold, which seeks to overturn the previously approved strategy. The Board highlighted concerns over the requisition plan, citing a lack of detail, credibility, and clarity on how much cash would be returned to investors. Risks outlined included being locked into an illiquid investment structure with high costs, weak deal flow prospects, and the requisitioners’ track record of fund underperformance.

Zytronic reiterated its unanimous commitment to returning all available cash to shareholders, emphasizing that this approach had been overwhelmingly approved by investors earlier in 2025. The Board urged shareholders to vote in favour of all AGM resolutions supporting the cash return and against the requisition resolutions at the October general meeting to safeguard value and protect returns.

This investor update underlines Zytronic’s focus on delivering shareholder value through disciplined execution of its liquidation strategy, transparent financial outcomes, and strong governance.

Capricorn Energy PLC delivered a mid-year 2025 investor update highlighting significant progress in reshaping the business, strengthening financial discipline, and positioning for sustainable growth. Under its refocused strategy, the Company has exited non-core activities, reduced G&A by around 80%, and returned more than $600 million to shareholders via dividends and buybacks. Management emphasised its self-funding model, strict capital discipline, and commitment to shareholder value.

In Egypt, Capricorn and partner Cheiron achieved a key milestone with government approval of a consolidated production sharing contract covering eight concessions. The new fiscal terms extend concession life, enhance cash flow, and support a larger reserves and production base, with ratification expected in H2 2025. Production guidance remains 17,000–21,000 boe/d, weighted 43% to liquids, while cost control and high-margin drilling remain priorities. Despite inflationary pressures and currency devaluation, collections from EGPC are improving, with $90 million expected in H2 to support debt repayment.

Operationally, Capricorn is advancing a four-rig drilling programme, well optimisation initiatives, and near-field exploration to unlock up to 350 million boe of contingent resources, with scope to convert 20 million boe to reserves in the near term. The Company continues to explore selective opportunities in the UK North Sea, guided by strict investment criteria, and remains open to synergistic M&A.

With a strengthened balance sheet, improving cash flow visibility, and enhanced Egyptian PSC terms, management sees potential to double share value in the near term while maintaining flexibility to balance reinvestment with further shareholder returns. Capricorn reiterated its focus on prudent risk management, operational efficiency, and disciplined capital allocation to deliver sustainable long-term value

Feedback PLC (“Feedback”), the specialist provider of digital infrastructure solutions to the NHS, reported FY2025 results highlighting strong operational progress with its Bleepa® platform, despite revenue headwinds. Revenue was £0.89m (down 25% year-on-year due to non-recurring items), with Bleepa contributing 90% of sales. EBITDA loss widened to £3.06m, reflecting lower revenue, modest headcount expansion and non-cash share-based charges, partly offset by tighter cost control. Following a successful £6.1m fundraising in November, Feedback ended the year with £5.95m cash, extending its runway into early 2027 even under a downside scenario.

Operationally, Bleepa demonstrated transformative impact within the NHS. At Queen Victoria Hospital, the platform enabled a 92% reduction in outpatient appointments and 63% reduction in waiting times, outcomes referenced by the UK Department of Health as a model for elective recovery. Further pathway pilots were delivered at Northern Care Alliance and Buckinghamshire, Oxfordshire & Berkshire ICP, alongside integration into national NHS systems such as e-Referral Service (ERS) and GP Connect. Feedback also signed an MOU with a leading primary care provider and secured the HSJ Partnership Award for clinical service redesign.

Looking ahead, the company is engaging directly with NHS England and the Department of Health to position Bleepa as core infrastructure for national elective recovery and community care initiatives, including Neighbourhood Health Delivery. While NHS decision-making has been delayed by structural reforms, Feedback remains aligned with government priorities to digitise care pathways, reduce waiting lists and shift delivery into community settings.

With proven clinical outcomes, strategic NHS integrations, and sufficient cash to deliver on its growth strategy, Feedback is well positioned to capture significant long-term opportunities in UK healthcare and beyond.

City of London Investment Group PLC (“CLIG”), the specialist global asset manager, released its June 2025 annual results, highlighting resilient performance, disciplined cost management, and a strong dividend track record. Funds under management rose 6% to over $11 billion, with average FUM for the year up 7%. Earnings per share increased 10% to 36.5p despite currency headwinds, while profit before tax advanced 13% to $30.8m, reflecting higher fee income and tight cost control. The cost-income ratio improved to 40%, down from 42% in FY2024.

CLIG has consistently delivered shareholder value since its 2006 listing, with a total return of 11.3% per annum and more than 520p distributed in dividends to date. A 22p final dividend has been proposed, bringing the full-year payout to 33p, equivalent to a 9% yield at current share prices. The Group maintains a debt-free balance sheet with robust cash flow to support sustainable dividends and future growth opportunities.

Performance across strategies was strong, with the flagship Emerging Markets mandate outperforming by over 500 basis points, alongside gains in International Equity, Opportunistic Value, and Listed Private Equity. CAP’s fixed income portfolios also outperformed benchmarks, underpinned by discount narrowing and corporate actions in closed-end funds. CLIG continues to benefit from diversification across equity and fixed income, with complementary strategies enhancing stability and long-term compounding returns.

Looking ahead, management sees growth opportunities in international and emerging markets as macro conditions shift, supported by $2.5bn of available capacity. Additional demand is expected for Listed Private Equity and Opportunistic Value strategies, alongside potential innovation in new products. CLIG remains committed to delivering consistent alpha, maintaining strong client relationships, and sustaining its market-leading dividend policy.

Advanced Medical Solutions Group PLC (AIM:AMS) delivered a strong interim results investor update for the six months ended 30 June 2025, highlighting robust revenue growth, strategic acquisitions, and improved profitability. Group revenue rose 66% at constant currency to £210.8m, driven by both organic growth and the successful integration of Peter Surgical and Syntol, with EBITDA up 42% to £24.4m and adjusted pre-tax profit rising 11% to £16.4m. LiquiBand remained a key growth driver, delivering 15% global sales growth, while the biosurgical portfolio rebounded 40% supported by efficiency gains from Syntol. The restructured wound care division returned to double-digit margins from Q2, with revenues up 18%. Integration synergies are on track, with AMS targeting £10m annualised EBITDA benefits by 2027 and additional commercial synergies of £5–10m by 2029. Strategic progress includes strong uptake of sutures, clips, and VTO products, advancing regulatory submissions in the US and China, and a strengthened product pipeline across adhesives, collagens, and bone substitutes. Despite temporary headwinds from US tariffs and legacy backorders, supply chain improvements and strong order books underpin management’s confidence in meeting full-year consensus expectations. The board declared a 10% interim dividend increase, reflecting confidence in AMS’s growth strategy, expanded geographic footprint, and operational leverage. With momentum in key markets, a clear path to margin expansion, and a focus on cash generation, AMS remains well positioned to deliver sustainable growth, shareholder value, and long-term profitability.

Corero Network Security PLC (CNS:AIM) delivered its H1 2025 interim results with strong momentum in its shift towards a SaaS and annual recurring revenue (ARR) model. ARR grew 25% year-on-year to $21.6 million, reflecting robust customer retention and accelerating adoption of Corero’s cybersecurity solutions. While reported revenue and EBITDA were impacted by the industry-wide transition from upfront Capex deals to subscription-based contracts, gross margins remained resilient at 91%, underscoring the scalability of the business model. Key wins included multi-million-dollar expansions with TierPoint and Forte Telecom, alongside new enterprise adoption at Cooper University Healthcare, highlighting both upsell strength and market diversification. Geographic expansion into Latin America, Asia-Pacific, and the Middle East continues to reduce reliance on U.S. sales, while alliances with major partners such as Juniper (now HPE Networking) are opening access to Tier 1 telcos and new verticals, including financial services and critical infrastructure under Europe’s DORA regulations. Management reaffirmed confidence in meeting revised full-year guidance, supported by a healthy order pipeline, growing global footprint, and leadership recognition in independent industry analyses. Positioned in a $4 billion and expanding cybersecurity market, Corero is leveraging its innovation in DDoS protection and Zero Trust Access solutions to capture share, build long-term recurring revenues, and enhance visibility for sustainable growth. Investors are encouraged to view ARR as the company’s key performance metric, underpinning stronger forward revenue visibility and profitability potential.

Mila Resources PLC (“Mila”) provided an investor update focused on its Queensland gold assets, highlighting strong progress in advancing exploration and unlocking shareholder value. The Company has secured an option over three highly prospective licences — Yarral, Mount Steadman and Manau — acquired from EMX Capital, all located in a Tier-1 mining jurisdiction surrounded by established producers. Initial drilling at Yarral validated historic high-grade intercepts, with every hole returning gold mineralisation, including standout results such as 17m at 5 g/t Au. Encouraged by Phase 1 success, Mila is now fully funded for its Phase 2 drilling campaign, targeting extensions to historic resources and working toward a maiden JORC-compliant resource estimate.

The Yarral project offers significant upside potential, with mineralisation confirmed along a 20km fault structure of which only 4km has been tested to date. Modern exploration methods, including updated geophysics, are being systematically applied for the first time in over 25 years, enhancing confidence in resource growth. Mila also sees opportunity across its wider portfolio, with promising gold and copper indications at Mount Steadman and Manau, while continuing to progress its Kathleen Valley asset.

Management emphasised disciplined cost control, a strong funding position, and a clear pathway to value creation through systematic exploration and resource definition. With Phase 2 drilling now commencing, Mila aims to demonstrate scale, deliver consistent newsflow through assays and exploration updates, and position itself as a key emerging gold player in Queensland.

Pennant International Group plc (PEN:AIM) delivered its latest investor update, outlining progress on its transformation into a scalable software and services business. Despite first-half revenue of £4.5m, an adjusted pre-tax loss of £1.8m and net debt of £2.1m, management highlighted strong momentum in its Auxilium software suite, which now represents a growing base of annual recurring revenue (£2.3m, expected to reach £2.5m by year-end). The transition of customers from perpetual licences to subscription models underpins future revenue visibility and margin growth. Strategic partnerships, including Siemens and new channels in Asia, Germany and India, are expected to accelerate software adoption, with Auxilium already gaining traction in sectors such as defence, aerospace, shipping, robotics and space. While the delayed £5.8m GenFly MOD contract impacted near-term cash flow and required a £1.25m equity raise, Pennant reported a strong order book with over £10m in advanced negotiations, providing confidence in contract wins through 2025–26. The company has restructured its training systems division to focus on higher-margin aftermarket opportunities and expects steady contribution from technical services as rail and data conversion markets recover. Looking ahead, Pennant forecasts FY25 revenues of c.£10m, underpinned by £9m of contracted sales, with growth in recurring software revenues and new training contracts supporting a return to positive adjusted PBT and cash flow in 2026. With a clear strategy, global partnerships and strong bid activity across defence and adjacent markets, Pennant is positioning itself as a leading provider of integrated software, training and technical services solutions that enhance operational readiness, asset availability and long-term customer value.

Eden Research PLC (EDEN:AIM) delivered an interim investor update highlighting progress on its sustainable crop-protection portfolio despite seasonal revenue phasing. Management reaffirmed FY (15 months to 31 March 2026) revenue guidance of c. £5m and noted a stronger cash position with no expected fundraise, as the company shifts its year-end to align with agricultural cycles. Commercial momentum included a key California label extension for Mevalone (powdery mildew in grapes), a new Kenyan distribution agreement with Andermatt, and a supply deal with Veto Pharma (thymol-based bee health). Regulatory and growth strategy catalysts remain central: full EU approval for the seed-treatment repellent (sold under emergency authorisations in Italy via Corteva) is expected to expand the addressable market and support margins and EBITDA; French approval for Mevalone on downy mildew could add ~€8m peak sales; and pipeline assets—an advanced broad-spectrum insecticide (INO20E) and a late-blight fungicide with strong trial efficacy—target meaningful medium-term revenue. Eden now has authorisations across 25 countries and 100+ crop uses, underpinned by partnerships with Corteva, Eastman Chemical, Sipcam Oxon and Andermatt. While H1 revenue was lower due to timing and logistics, management emphasized product performance, disciplined execution, and regulatory milestones as drivers of company performance, financial results, revenue growth and long-term value for investors.

M Winkworth PLC (AIM: WINK) delivered a strong performance in its interim results for H1 2025, underpinned by growth in both sales and lettings and continued investment in its franchise network. Network revenue rose 15% to £32m, with sales revenue up 27% to £16.9m and lettings revenue increasing 3% to £15.1m, marking the best-ever first half for the group. Total company revenue edged up 1% to £5.2m, while profit before tax was £0.83m, reflecting higher one-off costs including investment in Prime Central London, a head office move, and systems development. Cash stood at £3.86m at period end, supporting a 10% increase in dividends to 6.6p per share. Winkworth expanded its footprint with three new offices and two refranchises, while strengthening its London presence through strategic investment and talent acquisition. The company highlighted strong momentum in outer London, buoyed by resilient family housing demand, alongside stable growth in managed lettings income despite a tighter rental market. With a low fixed-cost franchise model, emphasis on digital investment, and a progressive dividend policy, Winkworth remains focused on backing high-quality operators, expanding its network, and sustaining long-term growth. Management reiterated its strategy of ensuring franchisees achieve top-three market positions, supported by strong brand recognition, operational efficiency, and a robust order book of growth opportunities. Investors can access the full presentation and Q&A via the Investor Meet Company platform.